However, attempts to treat glioblastoma with targeted EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, lapatinib, and afatinib, have remained largely unsuccessful [10,11,12]. The gene discussed is EGFR; the disease is glioblastoma.